Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials

Wei Xin1, Wei Wei2 and Xiaoying Li1*

Abstract

Background: Effects of fish oil on systematic inflammation in chronic heart failure remain unclear. In this meta-analysis, we aimed to evaluate the influence of fish oil supplementation on circulating levels of inflammatory markers in patients with chronic heart failure.

Methods: Human randomized controlled trials, which compared the effects of fish oil supplementation with placebo in patients with chronic heart failure, were identified by systematic search of Medline, Embase, Cochrane’s library and references cited in related reviews and studies up to November 2011. Outcome measures comprised the changes of circulating inflammatory markers. Meta-analysis was performed with the fixed-effect model or random-effect model according to the heterogeneity.

Results: A total of seven trials with eight study arms were included. The pooled results indicated circulating levels of tumor necrosis factor α (SMD = -0.62, 95% CI -1.08 to -0.16, p = 0.009), interleukin 1 (SMD = -1.24, 95% CI -1.56 to -0.91, p < 0.001) and interleukin 6 (SMD = -0.81, 95% CI -1.48 to -0.14, p = 0.02) were significantly decreased after fish oil supplementation; however, high sensitivity C reactive protein, soluble intracellular adhesion molecule 1 and vascular cell adhesion molecule 1 were not significantly affected. Meta-regression and subgroup analysis results suggested the difference in dose of fish oil and follow-up duration might influence the effects of fish oil on tumor necrosis factor α and interleukin 6. Greater reduction of these two markers might be achieved in patients taking fish oil of a higher dose (over 1000 mg/day) or for a longer duration (over 4 months).

Conclusions: Limited evidence suggests anti-inflammation may be a potential mechanism underlying the beneficial effects of fish oil for chronic heart failure. Further large-scale and adequately powered clinical trials are needed to confirm these effects.

Keywords: Fish oil, Omega 3 polyunsaturated fatty acids, Heart failure, Inflammatory markers, Meta-analysis

Background

Chronic heart failure (CHF) is a common clinical syndrome which can be caused by various cardiovascular disorders [1-3]. Despite recent advances in therapeutic strategies, CHF is still one of the leading causes of morbidity and mortality worldwide [4,5]. Although current treatments improve clinical symptoms and slow progression of cardiac dysfunction, the prognoses for patients with CHF remain poor [5,6]. Therefore, there is an urgent need for development of novel therapy for CHF.

Fish oil, mainly consisting of two categories of marine omega 3 polyunsaturated fatty acids (PUFAs) - eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA), has been suggested to be a potential adjunctive therapy for many cardiovascular disorders, including CHF [7,8]. A recent clinical trial [9] showed a statistically significant improved mortality or cardiovascular hospitalizations (-8%; p < 0.01) in patients with CHF who received additional fish oil supplementation. However, the exact mechanisms underlying benefits of fish oil to patients with CHF are not fully understood. Inflammation plays

* Correspondence: lixy301@163.com
1First Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, Peoples Republic of China
Full list of author information is available at the end of the article

© 2012 Xin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
an important role in the pathogenesis and progression of CHF [10,11]. Levels of circulating inflammatory markers, including high sensitivity C reactive protein (hsCRP), tumor necrosis factor alpha (TNF-α), interleukin 1 (IL-1), interleukin 6 (IL-6), soluble intracellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) et al., were elevated in patients with CHF, serving as prognostic markers or therapeutic targets [11-14]. Fish oil has been suggested to exert anti-inflammation effects in patients with CHF [7,8,15]. However, clinical trials in humans have shown inconsistent results [16-23]. Herein, we aimed to evaluate the effects of fish oil on levels of the above inflammatory markers in CHF through meta-analysis of randomized, placebo-controlled clinical trials.

Methods
Search strategy
We systematically searched Pubmed (from 1950 to November, 2011), Embase (from 1966 to November, 2011) and the Cochrane Library (Cochrane Center Register of Controlled Trials) for relevant records, using the term “omega-3 fatty acids”, “fish oil”, “fish-oil”, “marine oil”, “eicosapentaenoic acid”, “EPA”, “docosahexaenoic acid”, “DHA”, “dietary therapy” paired with the following: “heart failure”, “cardiac failure”, “cardiac dysfunction”, “ventricular dysfunction”, “ventricular insufficiency”, and “cardiomyopathy”. The search was limited to studies in human. We also analyzed reference lists of original and review articles using a manual approach.

Study selection
Studies were selected for analysis if they met the following criteria: 1) published as full-length articles in any language; 2) reported as a prospective, randomized, and placebo-controlled trial with either a parallel or a crossover design (regardless of sample size); 3) analyzed adult patients with established CHF (regardless of the etiology and severity of the disease) who were assigned to oral fish oil supplementation or placebo for at least one month in addition to concurrent therapy; 4) reported data on levels of at least one of the following circulating inflammatory factors, including hsCRP, TNF-α, IL-6, IL-1, sICAM-1 or sVCAM-1.

Data extraction and quality assessment
Searching, data extraction, and quality assessment were completed independently by two authors (WX and WW) according to inclusion criteria. Discrepancies were resolved by consensus. Extracted data included study design characteristics, patient characteristics (number, age, sex, cardiac function, baseline circulating levels of inflammatory markers, and concurrent medications), intervention strategies (dose of EPA and DHA, ratio of EPA to DHA and composition of placebo), follow-up duration, and means and standard deviations (SDs) for changes of the aforementioned inflammatory markers from baseline. If the study provided medians and interquartile ranges (IQRs) instead of means and SDs, we imputed the means and SDs as described previously [24]. For studies with multiple intervention groups (e.g. with different doses of fish oil), we split the shared control group into two or more groups with smaller sample size to overcoming a unit-of-analysis error, and included these two or more comparisons into the meta-analysis according to the instruction of Cochrane’s Handbook [25].

The quality of the studies was judged by quality of randomization, generation of random numbers, concealment of treatment allocation, blinding, and reporting of withdrawals. Trials scored one point for each area addressed, with a possible score between 0 and 5, where 5 represented the highest level of quality [26].

Statistical analysis
All endpoints were estimated based on the change from baseline to follow-up, and pooled effects were presented as standardized mean difference (SMD) with 95% confidence intervals (CI) because various measurements were applied in the included studies. Inter-study heterogeneity was formally tested using Cochrane’s Q test, and significant heterogeneity was considered existing if p value was < 0.10. The I² statistic was also examined, and a value of I² > 50% indicated significant heterogeneity among the trials [27]. If above tests showed no significance of heterogeneity among the included trials, fixed-effect model was used to calculate SMD and its 95% CI. By contrast, if there is significant heterogeneity among the included studies, random-effect model was applied [28]. Meta-regression analysis and predefined subgroup analysis was performed to explore the possible source of heterogeneity. Furthermore, potential publication bias was assessed with Egger regression asymmetry test [29] and funnel plots; p values were two-tailed and statistical significance was set at 0.05. Meta-analysis and statistical analysis was performed with Stata software (version 12.0; Stata Corporation, College Station, TX) and RevMan software (version 5.1; Cochrane Collaboration, Oxford, United Kingdom).

Results
Search results
A total of 1250 records were identified, and 1210 were excluded because they did not describe randomization or controlling, or because the objectives of these studies were irrelevant to the present meta-analysis. Of the 40 potentially relevant records screened, eight met the selection criteria for the current meta-analysis [16-23] (Figure 1). Thirty-two records were excluded because
the participants in 25 trials were not patients with CHF; 5 trials didn’t report any data of related outcomes; 1 trial included children with CHF and 1 trial reported incomplete data of related outcomes.

Study characteristics
Two of the included records reported the outcomes of different inflammatory markers from the same study population (one record of hsCRP [21], the other of TNF-α and IL-6 [22]), which makes a total of 7 trials included. This trial by Moertl et al. [21,22] included two intervention groups of different doses of fish oil (a higher dose group of 3360 mg/d and a lower dose group of 840 mg/d), which we included in our study separately. Overall, a total of 8 study arms from 7 trials were included in this meta-analysis (Table 1 and Table 2), of which 6 had a parallel design [16,18-23] and 1 had a crossover design [17].

All of the studies declared that the participants were clinically and hemodynamically stable CHF patients who received optimal medical therapy based on modern CHF treatment strategies, including diuretics and neurohormonal inhibitors, and the medication treatment was maintained during the follow-up interval. Statins were also taken by 83%, 54% and 14% of the participants in three of the studies [17,20,23], not taken in one study [16], and not reported in the rest three studies [18,19,21,22]. The mean age of the participants of the included studies varied from 57 to 73. The etiology of CHF is exclusively ischemic in 1 trial [17], non-ischemic in 3 trials [18,21-23], and from both in 3 trials [16,19,20]. Only one study reported inclusion of the CHF patients primarily caused by myocarditis (5 of the 43 included participants) [22]. However, patients with acute myocarditis were excluded from this study. The baseline cardiac functions were of classes I – IV defined by New York Heart Association (NYHA) and the baseline left ventricular ejection fraction (LVEF) of the participants varied from 17% to 36%. The dosage of fish oil (calculated as total dose of EPA and DHA) ranged from 600 mg/day to 5440 mg/day, with the ratio of EPA to DHA varying from 0.38 to 1.83. The duration of the investigation varied from 3 months to 12 months.

Data quality
The quality score of the 7 trials ranged form 3 to 5. All of the included trials were randomized and placebo-controlled, with 6 studies in a double-blind fashion [16-18,20-23] and 1 in a single-blind fashion [19]. Two of the trials reported methods of random sequence generation [19,21,22], while only one study reported allocation concealment [21,22]. Details of withdrawals were reported in all of the 7 included trials.

Effects of fish oil supplementation on hsCRP in CHF
Four trials [17,19-21] including 5 study arms investigated the effects of fish oil supplementation on hsCRP levels in CHF patients (Table 2), but none of these studies showed a significant effect. No significant heterogeneity was found between the 5 study arms ($I^2 = 0.0\%$, $p = 0.954$), therefore the fixed-effect model was applied. The pooled results indicated that additional supplementation of fish oil didn’t significantly reduce the circulating level of hsCRP (SMD = -0.02, 95% CI -0.26 to 0.21, $p = 0.84$; Figure 2) in patients with CHF. Sensitivity analysis, excluding the two study arms in which hsCRP data were imputed from median and IQRs [21], also suggested an insignificant effect (SMD = -0.02, 95% CI -0.27 to 0.23, $p = 0.87$).

In view of the fact that statistical heterogeneity existed across the enrolled study arms, we performed meta-regression analysis including some predefined covariates for the hsCRP data.
| Study         | No. of patients | Mean age | Male % | Ischemic etiology | Mean NYHA | Mean LVEF % | ACEI/ARB % | β-blocker % | Statins % | EPA + DHA dose mg/d | EPA dose mg/d | DHA dose mg/d | EPA/DHA ratio | Duration months | Placebo study design | Study design | Quality score |
|--------------|-----------------|----------|--------|-------------------|-----------|-------------|-------------|-------------|-----------|--------------------|----------------|---------------|-----------------|----------------|-------------------|--------------|---------------|
| Mehra 2006   | 14              | 60       | 71     | 43                | III-IV    | 17          | 93          | 64          | 0         | 5440               | 3520           | 1920          | 1.83           | 4              | Corn oil R, DB, PC | 3            |               |
| O'Keefe 2006 | 18              | 68       | 100    | 100               | NR        | NR          | 78          | 83          | 0         | 810                | 225            | 585           | 0.38           | 4              | Corn oil & olive oil | R, DB, PC, CO | 3              |
| Nodari 2009  | 44              | 63       | 91     | 0                 | II-III    | 36.2        | 100         | 100         | NR        | 1440               | 540            | 900           | 0.60           | 6              | Olive oil R, DB, PC | 3            |               |
| Zhao 2009    | 75              | 73       | 73     | 64                | II-III    | 31          | 100         | 87          | NR        | 600                | 360            | 240           | 1.50           | 3              | NR R, SB, PC | 3            |
| Eschen 2010  | 138             | 60       | 86     | 68                | II-III    | 32          | 95          | 88          | 54        | 900                | 490            | 410           | 1.20           | 6              | Olive oil R, DB, PC | 3            |               |
| Moertl 2011a | 22              | 57       | 83     | 0                 | III-IV    | 24.3        | 100         | 100         | NR        | 840                | 465            | 375           | 1.24           | 3              | Gelatin R, DB, PC | 5            |               |
| Moertl 2011b | 21              | 60       | 94     | 0                 | III-IV    | 24.2        | 100         | 100         | NR        | 3360               | 1860           | 1500          | 1.24           | 3              | Gelatin R, DB, PC | 5            |               |
| Nodari 2011  | 133             | 63       | 75     | 0                 | II-I      | 36.5        | 100         | 100         | 14        | 1950               | 730            | 1220          | 0.60           | 12             | Olive oil R, DB, PC | 3            |               |

The study by Moertl et al. includes two intervention groups of different dosages of EPA + DHA (Moertl 2011a, EPA + DHA 840 mg/day and Moertl 2011b, EPA + DHA 3360 mg/day).

NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; R, random; DB, double blind; SB, single blind; PC, placebo-controlled; CO, crossover; NR, not reported.
to explore the potential sources of heterogeneity. The results indicated that follow-up duration was negatively related to effect size (regression coefficient = -0.12, 95% CI -0.19 to -0.05, p = 0.009), which largely explained the heterogeneity of the effect (Figure 3A). The mean age, gender of the participants, etiology of CHF, baseline LVEF, baseline TNF-α, doses of EPA or DHA, total dose of fish oil and the ratio of EPA to DHA were not significant modifiers to the effects of fish oil supplementation on TNF-α.

Additionally, we conducted a predefined subgroup analysis to observe the influence of study characteristics to the effects of fish oil supplementation on TNF-α (Table 3). The results showed that the differences in total dose of fish oil and the follow-up duration might influence the effects of fish oil on TNF-α significantly. Specifically, fish oil supplementation with total dose over 1000 mg/day or for duration over 4 months seemed to associate with a more remarkable reduction of TNF-α.

Effects of fish oil supplementation on IL-1
Only two trials [18,23] reported the effects of fish oil supplementation on IL-1 in CHF (Table 2), between which no significant heterogeneity was found (I² = 46.0%, p = 0.173). The pooled results indicated that fish oil reduced the level of circulating IL-1 (SMD = -1.24, 95% CI -1.56 to -0.91, p < 0.001; Figure 3B) in patients with CHF.

Effects of fish oil supplementation on IL-6
Five trials [17-19,22,23] including 6 study arms reported the effects of fish oil on IL-6 in CHF (Table 2). Significant heterogeneity was found among these study arms (I² = 85.8%, p < 0.001). The pooled results indicated that fish oil significantly reduced the level of circulating IL-6 (SMD = -0.81, 95% CI -1.48 to -0.14, p = 0.02; Figure 3C) in patients with CHF. However, sensitivity analysis, excluding the two study arms in which IL-6 data were imputed from median and IQRs [22], suggested an insignificant effect of fish oil on IL-6 (SMD = -0.81, 95% CI -1.72 to 0.10, p = 0.08).

The results of meta-regression analysis include some predefined covariates indicated that follow-up duration was negatively related to effect size (regression coefficient = -0.016, 95% CI -0.004 to -0.028, p = 0.017), which may partially explain the heterogeneity of the effect (Figure 3C).

Subgroup analysis showed that the differences in total dose of fish oil and the follow-up duration might influence the effects of fish oil on IL-6. Specifically, fish oil supplementation with a dose over 1000 mg/day or for duration over 4 months seemed to relate to a greater reduction of circulating IL-6 (Table 3).

Table 2 Mean baseline circulating levels of the inflammatory markers

| Study      | hsCRP μg/ml | TNF-α pg/ml | IL-1 pg/ml | IL-6 pg/ml | sICAM-1 pg/ml | sVCAM-1 pg/ml |
|------------|-------------|-------------|------------|------------|---------------|---------------|
| Mehra 2006 | NR          | 1.5         | NR         | NR         | NR            | NR            |
| O’Keefe 2006 | 1.3         | 6.7         | NR         | 1.6        | NR            | NR            |
| Nodari 2009 | NR          | 19.0        | 402.0      | 7.15       | NR            | NR            |
| Zhao 2009  | 5.6         | 61.5        | NR         | 11.3       | 1.0           | 1.6           |
| Eschen 2010 | 2.1         | NR          | NR         | 0.3        | 0.7           |               |
| Moertl 2011 a | 5.0         | 2.5         | NR         | 3.7        | NR            | NR            |
| Moertl 2011 b | 5.0         | 2.3         | NR         | 3.2        | NR            | NR            |
| Nodari 2011 | NR          | 23.0        | 483.0      | 10.6       | NR            | NR            |

The study by Moertl et al. includes two intervention groups of different dosages of EPA + DHA (Moertl 2011a, EPA + DHA 840 mg/day and Moertl 2011b, EPA + DHA 3360 mg/day).

hsCRP, high sensitivity C reactive protein; TNF-α, tumor necrosis factor α; IL-1, interleukin 1; IL-6, interleukin 6; sICAM-1, soluble intracellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; NR, not reported.
Figure 3 (See legend on next page.)
Effects of fish oil supplementation on sICAM-1 and sVCAM-1

Only two studies [19,20] reported the effects of fish oil supplementation on sICAM-1 and sVCAM-1 (Table 2). For sICAM-1, estimation of the overall effects were performed with random-effect model because significant heterogeneity was found ($I^2 = 86.5\%, p = 0.006$); while for sVCAM-1, fixed-effect model was applied because no significant heterogeneity was found ($I^2 = 48.8\%, p = 0.162$). The pooled results indicated that additional supplementation of fish oil didn’t affect the levels of circulating sICAM-1 or sVCAM-1 (sICAM-1: SMD = -0.19, 95% CI -0.97 to 0.58, p = 0.63, Figure 4A; sVCAM-1: SMD = -0.06, 95% CI -0.33 to 0.21, p = 0.65, Figure 4B). Meta-regression and subgroup analysis was not performed for these outcomes because of the limited number of studies included.

Publication bias

Publication bias was tested based on the data of TNF-\(\alpha\), which included the most study arms. Funnel plot (Figure 5) and Egger regression asymmetry test of the 7 included study arms suggested no significant publication bias for TNF-\(\alpha\) (Egger test, $p = 0.372$).

Discussion

In this meta-analysis, we summarized evidence from 7 published intervention trials that investigated the effects of fish oil supplementation on circulating markers of inflammation in patients with CHF. The results showed that fish oil reduced the circulating levels of TNF-\(\alpha\), IL-1 and IL-6 in patients with CHF, although the levels of hsCRP, sICAM-1 and sVCAM-1 were not significantly affected. Results of meta-regression and subgroup analysis suggested that supplementation with higher dose of fish or for a longer follow-up duration might associate with more remarkable reduction of TNF-\(\alpha\) and IL-6 levels. These results suggested that anti-inflammation may be a mechanism underlying the potential benefits of fish oil for patients with CHF.

Results of a few epidemiologic studies demonstrated that fish consumption or fish oil intake was inversely associated with incidence of CHF in general population [30-32]. Furthermore, recently published GISSI-HF trial [9] showed that in patients with CHF on evidence-based therapy, long term treatment with fish oil reduced combined endpoint of mortality or hospitalizations for cardiovascular reasons. Besides, our recently published meta-analysis also indicated that fish oil supplementation can favorably affect the cardiac function and functional capacity in CHF patients [33]. However, the exact mechanisms of these beneficial effects of fish oil to patients with CHF are not fully understood [15].

Accumulating evidence from animal experiments and clinical investigations have revealed that CHF may at least partially be an inflammatory disease, where various cytokines and adhesion molecules are involved in CHF pathogenesis and progression via contribution to endothelial dysfunction, cardiomyocyte apoptosis, cardiac remodeling and left ventricular dysfunction [10,34-36]. These inflammatory markers, including hsCRP, TNF-\(\alpha\), IL-1, IL-6, ICAM-1 and sVCAM-1 et al., were found to be elevated in patients with CHF [37-42], and were associated with the severity of the disease and the prognosis of the patients [11-13]. Moreover, experimental evidence suggested that inflammation may also be a treatment target for CHF, and suppression of the above inflammatory factors or inhibition their adverse biological effects in CHF may be of great potential therapeutic significance [14,36].

It has been suggested that fish oil supplementation may exert anti-inflammation effects by decreasing the production of inflammatory cytokines and adhesion molecules in some of the inflammation associated diseases, such as rheumatoid arthritis, inflammatory bowel diseases and asthma, but there were also studies didn’t support this concept [43,44]. Furthermore, a recent systematic review in healthy subjects, subjects with cardiovascular risk and established cardiovascular disease indicated that intervention studies with fish oil in these population demonstrated rather different results on inflammatory markers, although the reasons for above controversy were unknown [45]. Since anti-inflammation was suggested to be involved in the therapeutic mechanisms of fish oil to cardiovascular disorders, we systematically evaluated the effects of additional fish oil supplementation on the circulating levels of inflammatory markers in CHF patients. The results of our meta-analysis indicated the suppressive effects of fish oil on circulating TNF-\(\alpha\), IL-1 and IL-6, suggesting the potential role of fish oil supplementation in blunting the inflammatory response associated with CHF and modifying the outcomes of these patients. Previous studies indicated that the potential mechanisms of fish oil on these inflammatory markers may involve its ability to modulation the nuclear transcription factor (NF-KB) [46,47], which subsequently inhibited transcription of...
## Table 3 Subgroup estimation of the effects of fish oil supplementation on TNF-α and IL-6 in patients with CHF

| Subgroup               | TNF-α Study arms (n)/patients (n) SMD [95% CI] | p<sup>※</sup> | IL-6 Study arms (n)/patients (n) SMD [95% CI] | p<sup>※</sup> |
|------------------------|-----------------------------------------------|---------------|---------------------------------------------|---------------|
| **Age**                |                                               |               |                                             |               |
| ≤ 60 years             | 3/57 -0.47 [-1.22, 0.27]                      | 0.80 [-1.45, -0.15] | 2/43 -0.80 [-1.45, -0.15] | 0.99         |
| > 60 years             | 4/285 -0.68 [-1.28, -0.08]                    | 0.67          | 4/285 -0.81 [-1.72, 0.10]                   | 0.99         |
| **Gender (male)**      |                                               |               |                                             |               |
| ≤ 90%                  | 4/244 -0.76 [-1.48, -0.03]                    | 2/43 -1.02 [-1.77, -0.28] | 0.67 | 0.99 | 4/285 -0.81 [-1.72, -0.10] | 0.99 |
| > 90%                  | 3/98 -0.44 [-0.87, -0.02]                     | 0.46          | 3/98 -0.60 [-1.92, 0.72]                    | 0.58         |
| **Ischemic CHF**       |                                               |               |                                             |               |
| Not excluded           | 3/125 -0.42 [-0.94, 0.09]                     | 2/111 0.05 [-1.17, 1.07] | 4/217 -1.33 [-1.74, -0.92] | 0.06 |
| Excluded               | 4/217 -0.71 [-1.34, -0.07]                    | 0.50          | 4/217 -1.33 [-1.74, -0.92]                   | 0.06         |
| **Baseline NYHA (class IV)** |                                           |               |                                             |               |
| Not included           | 3/249 -0.85 [-1.51, -0.18]                    | 3/249 -1.23 [-1.93, -0.54] | 0.47 | 0.37 | 3/249 -1.23 [-1.93, -0.54] | 0.37 |
| Included               | 3/57 -0.47 [-1.22, 0.27]                      | 0.47          | 2/43 -0.80 [-1.45, -0.15]                   | 0.37         |
| **Baseline LVEF**      |                                               |               |                                             |               |
| ≤ 30%                  | 3/249 -0.85 [-1.51, -0.18]                    | 3/249 -1.23 [-1.93, -0.54] | 0.47 | 0.37 | 3/249 -1.23 [-1.93, -0.54] | 0.37 |
| > 30%                  | 3/249 -0.47 [-1.22, 0.27]                     | 0.47          | 2/43 -0.80 [-1.45, -0.15]                   | 0.37         |
| **Baseline TNF-α**     |                                               |               |                                             |               |
| ≤ 10 pg/ml             | 4/93 -0.33 [-0.82, 0.17]                      | —             | —                                           | —             |
| > 10 pg/ml             | 3/249 -0.85 [-1.51, -0.18]                    | 0.22          | —                                           | —             |
| **Baseline IL-6**      |                                               |               |                                             |               |
| ≤ 5 pg/ml              | —                                              | —             | 3/79 -0.31 [-1.27, 0.65]                    | —             |
| > 5 pg/ml              | —                                              | —             | 3/249 -1.23 [-1.93, -0.54]                   | 0.13         |
| **ACEI/ARB**           |                                               |               |                                             |               |
| Not all used           | 1/14 -1.41 [-2.62, -0.19]                     | 0/0           | —                                           | —             |
| All used               | 5/292 -0.62 [-1.17, -0.08]                    | 0.25          | 5/292 -1.10 [-1.60, -0.60]                   | —             |
| **β-blockers**         |                                               |               |                                             |               |
| Not all used           | 3/125 -0.42 [-0.94, 0.09]                     | 2/111 0.05 [-1.17, 1.07] | — | — | 2/111 0.05 [-1.17, 1.07] | — |
| All used               | 4/217 -0.71 [-1.34, -0.07]                    | 0.50          | 4/217 -1.33 [-1.74, -0.92]                   | 0.06         |
| **EPA + DHA**          |                                               |               |                                             |               |
| ≤ 1000 mg/d            | 3/133 -0.23 [-0.57, 0.11]                     | 3/133 -0.26 [-1.06, 0.54] | 0.22 | 0.67 | 3/133 -0.26 [-1.06, 0.54] | 0.67 |
| > 1000 mg/d            | 4/209 -1.01 [-1.50, -0.53]                    | 0.01          | 3/195 -1.47 [-1.84, -1.11]                   | 0.007        |
| **EPA**                |                                               |               |                                             |               |
| ≤ 800 mg/d             | 4/266 -0.51 [-1.20, 0.19]                     | 4/266 -0.62 [-1.54, 0.29] | 0.56 | 0.28 | 4/266 -0.62 [-1.54, 0.29] | 0.28 |
| > 800 mg/d             | 3/76 -0.76 [-1.25, -0.27]                     | 2/62 -1.25 [-1.93, -0.56] | 0.28 | 0.76 | 2/62 -1.25 [-1.93, -0.56] | 0.28 |
| **DHA**                |                                               |               |                                             |               |
| ≤ 1300 mg/d            | 4/266 -0.51 [-1.20, 0.19]                     | 4/266 -0.62 [-1.54, 0.29] | 0.56 | 0.28 | 4/266 -0.62 [-1.54, 0.29] | 0.28 |
| > 1300 mg/d            | 3/76 -0.76 [-1.25, -0.27]                     | 2/62 -1.25 [-1.93, -0.56] | 0.28 | 0.76 | 2/62 -1.25 [-1.93, -0.56] | 0.28 |
| **EPA DHA ratio**      |                                               |               |                                             |               |
| ≤ 1                    | 3/210 -0.80 [-1.53, -0.07]                    | 3/210 -0.88 [-1.20, 0.44] | 0.08 | 0.44 | 3/210 -0.88 [-1.20, 0.44] | 0.44 |
| > 1                    | 4/132 -0.38 [-0.79, 0.03]                     | 3/118 -0.66 [-1.04, -0.29] | 0.76 | 0.76 | 3/118 -0.66 [-1.04, -0.29] | 0.76 |
| **Duration**           |                                               |               |                                             |               |
| ≤ 4 months             | 5/168 -0.32 [-0.63, -0.01]                    | 4/154 -0.38 [-1.02, 0.26] | 0.008 | 0.008 | 4/154 -0.38 [-1.02, 0.26] | 0.008 |
| > 4 months             | 2/174 -1.15 [-1.67, -0.62]                    | 0.008 | 2/174 -1.59 [-1.93, -1.25]                   | 0.001        |
| **Quality score**      |                                               |               |                                             |               |
| ≤ 3                    | 5/299 -0.77 [-1.32, -0.22]                    | 4/285 -0.81 [-1.72, 0.10] | 0.15 | 0.99 | 4/285 -0.81 [-1.72, 0.10] | 0.99 |
| > 3                    | 2/43 -0.16 [-0.78, 0.46]                      | 0.15          | 2/43 -0.80 [-1.45, -0.15]                   | 0.99         |

<sup>※</sup> difference between strata (Student’s t test).

TNF-α, tumor necrosis factor α; IL-6, interleukin 6; CHF, chronic heart failure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor inhibitor; EPA, eicosapentaenoic acid; DHA, docosahexenoic acid; SMD, standardized mean difference; CI, confidence interval.
above inflammatory markers in CHF. Besides, recent evidence suggested that fish oil may transcriptionally up-regulate adiponectin, a potential anti-inflammatory factor, thereby suppressing above inflammatory cytokines [48,49].

Considering the significant heterogeneity that existed in the pooled analysis of TNF-α and IL-6, we performed meta-regression and predefined subgroup analysis to explore the potential sources. The results suggested that the dose and follow-up duration of fish oil supplementation might influence the effects of fish oil on circulating levels of TNF-α and IL-6 in patients with CHF, and a higher dose of fish oil or a longer follow-up duration seem to be associated with a more remarkable reduction of circulating levels of TNF-α and IL-6. Notably, for the studies included in meta-analysis of IL-1 [18,23], the doses of fish oil are over 1000 mg/day and the follow-up durations are 6 to 12 months, which made the pooled result a reduction of IL-1 by fish oil supplementation.

High sensitivity C reactive protein is considered to be of prognostic value in many cardiovascular diseases [50,51], including CHF [13]. However, the pooled results of our meta-analysis failed to demonstrate a significant effect of fish oil supplementation on circulating level of hsCRP in patients with CHF. These results are supposed to be robust, because none of the included studies in meta-analysis of hsCRP showed a significant influence of fish oil supplementation on circulating hsCRP levels, and the heterogeneity among these studies was very little. The nonsignificant efficacy of fish oil supplementation on circulating hsCRP levels in the included CHF patients of this meta-analysis may be explained by the following two reasons. First, the patients of the included studies were in stable clinical and hemodynamical conditions receiving treatment of the optimal medications.
(including neurohormonal inhibitors in all studies and statins in some studies) according to the current guidelines. Therefore, the mean baseline circulating levels of hsCRP for the participants of included studies were relatively low (1.3 to 5.6 μg/ml, Table 2) and additional supplementation of fish oil had little effect on it. Second, the low number of included studies (4 studies) and the small size of the included population (285 patients) may make the analysis underpowered to show significant effect.

Our meta-analysis also failed to show a significant efficacy of fish oil supplementation on the levels of sICAM-1 and sVCAM-1 in CHF. These results, from our point of view, may also be attributed to the low number of included studies (2 studies) and the small size of the included population (213 patients). Several potential limitations should be addressed regarding the present meta-analysis. First, the numbers of studies and patients included in this meta-analysis were small, so results of some of estimations, such as for the effects of fish oil supplementation on IL-1, sICAM-1 and sVCAM-1, should be interpreted with caution. Second, because baseline data of statins using in half of the included study arms were unavailable, we were unable to estimate the effects of statins using on the pooled analysis of the inflammatory markers. This may be an important source of heterogeneity. Third, as for the subgroup analysis, the number of included studies and patients in each stratum is relatively small. Besides, we did not have access to individual patient data. Some subgroup analysis of CHF patients might show a difference with fish oil supplementation if larger numbers of patients were included or individual patient data were available (e.g. fish oil supplementation on circulating IL-6 in ischemic and non-ischemic CHF patients). Fourth, this meta-analysis included one study [21,22] in which the data were imputed from median and IQRs for some outcomes. Although inclusion of the imputed data may add to the potential bias, sensitivity analysis by excluding this study showed generally consistent results with which all the studies were included. Furthermore, we considered this as the best possible approach to not exclude valuable data from related studies.

Conclusion
In conclusion, our meta-analysis, by pooling the limited trials available currently, indicates that additional supplementation of fish oil may reduce the circulating levels of TNF-α, IL-1 and IL-6 in patients with CHF, although the levels of hsCRP sICAM-1 and sVCAM-1 were not significantly affected. Also, greater reduction of TNF-α and IL-6 might be seen in patients who take fish oil in a higher dose or for a longer duration. These results suggested that anti-inflammation might be a possible mechanism underlying the potential beneficial effects of fish oil supplementation to patients with CHF. Additionally, large-scale randomized controlled trials with adequate power are warranted in the future to confirm these effects.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
XL conceived of the study idea and XL and WX contributed to the study design. WX conducted the literature review. WX and WW performed the data extraction and all authors were involved in consensus agreements concerning data discrepancies. WX and XL drafted the manuscript. All authors were involved in revising the article for important intellectual content, interpreting the data, and approved the final version to be published.

Acknowledgments
The authors would like to thank Dr. Deddo Moertl and Dr. Mandeep Mehra for their sharing unpublished baseline data of their studies for this analysis.

Author details
1 First Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, Peoples Republic of China. 2 Department of pathophysiology, Medical College of Nankai University, Tianjin, Peoples Republic of China.

Received: 10 April 2012 Accepted: 18 September 2012 Published: 20 September 2012

References
1. Braunwald E, Bristow MR: Congestive heart failure: fifty years of progress. Circulation 2000, 102:v14-v23.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, et al: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, Van VDD, Atar D, Hoes AW, et al: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
4. Fang J, Mensah GA, Croft JB, Keenan NL: Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008, 52:428-434.
5. Najafi F, Jamrozik K, Dobson AJ: Understanding the 'epidemic of heart failure': a systematic review of trends in determinants of heart failure. Eur J Heart Fail 2009, 11:472-479.
6. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Barry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, et al: Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 2011, 123:e18–e1809.
7. Witte KK, Clark AL: Fish oils-adjutant therapy in chronic heart failure. Eur J Cardiovasc Prev Rehabil 2004, 11:267-274.
8. Marchiolò R, Silletta MG, Levantesi G, Pioggiarella R, Tognoni G: N-3 polyunsaturated fatty acids in heart failure: mechanisms and recent clinical evidence. Cell Mol Biol (Nony-le-Grand) 2010, 56:110–130.
9. Tavazzi L, Maggioni AP, Marchiolò R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure [the GISSI-HF trial]: a randomised, double-blind, placebo-controlled trial. Lancet 2000, 372:1223–1230.
Polyunsaturated fatty acids in heart failure: should...

10. Anker SD, Von HS: Inflammatory mediators in chronic heart failure: an overview. Heart 2004, 90:464–470.

11. Borkburt B, Mann DL, Deswal A: Biomarkers of inflammation in heart failure. Heart Fail Rev 2010, 15:331–341.

12. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, Lin SJ, Young MS: The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail 2003, 5:507–516.

13. Araujo JP, Lourenco P, Azevedo A, Fricos F, Rocha-Goncalves F, Ferreira A, Bettencourt P: Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Card Fail 2009, 15:256–266.

14. Heymans S, Hinch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filipotas G, Felix SB, Gullestad L, et al: Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009, 11:119–129.

15. Tang WH, Samara MA: Polysaturated fatty acids in heart failure: should we give more and give earlier. J Am Coll Cardiol 2011, 57:880–883.

16. Metra MR, Lavi CJ, Ventura HO, Milani RV: Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant 2006, 25:834–838.

17. O’Keefe JH Jr, Abuissa H, Sastre A, Steinhaus DM, Harris WS: Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 2006, 97:1127–1130.

18. Nodari S, Metra M, Milis G, Manera B, Cesana BM, Gheorghiade M, Dei CI. The role of n-3 PUFA in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther 2009, 23:5–15.

19. Zhao YT, Shao L, Tang LL, Hu B, Luo Y, Yu X, Zhang DF, Zhang H: Effects of n-3 polysaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J Int Med Res 2007, 35:1831–1941.

20. Eschen Q, Christensen JH, LA RMT, Romano P, Sala P, Schmidt EB: Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure. Cell Mol Biol (Noisy-le-Grand) 2010, 56:45–51.

21. Moertl D, Berger R, Hammer A, Hutuleac R, Kopp CW, Koppensteiner R, Kopp EN, Levy JT, May RB, Mayne ST. Dose-dependent decrease of platelet activation and tissue factor by omega-3 polysaturated fatty acids in patients with advanced chronic heart failure. Thromb Haemost 2011, 106:657–665.

22. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3 polysaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 2011, 161(6):e1–e9.

23. Nodari S, Trigiani M, Campia U, Manera A, Milei J, Cesana BM, Gheorghiade M, Dei CI. Effects of n-3 polysaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011, 57:870–879.

24. Hozo SP, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13.

25. Higgins JP, Green S (Eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

26. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet 1998, 352:609–613.

27. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557–560.

28. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177–188.

29. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629–634.

30. Mozaffarian D, Buysson CL, Lemaitre RN, Burke GL, Siscovick DS. Fish intake and risk of incident heart failure. J Am Coll Cardiol 2005, 45:2015–2021.

31. Yamagishi K, Nettleton JA, Folsom AR: Plasma fatty acid composition and incident heart failure in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008, 156:965–974.

32. Levitan EB, Wolk A, Miller MA: Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men. Eur Heart J 2009, 30:1495–1500.

33. Xin W, Wei W, Li X: Effects of fish oil supplementation on cardiac function in chronic heart failure: a meta-analysis of randomised controlled trials. Heart 2012, doi:10.1136/heartjnl-2012-302119.

34. Toussil D, Charakida M, Stefanadis C: Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol 2005, 100:347–353.

35. Yndestad A, Damsa JK, Oie E, Ueland T, Gullestad L, Aukrust P: Systemic inflammation in heart failure—the whys and wherefores. Heart Fail Rev 2006, 11:83–92.

36. McInerney TA: Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med 2011, 17:343–441.

37. Levine B, Kalmann J, Mayer L, Fillit HM, Parker M. Elevating circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236–241.

38. Pye M, Rie AP, Cobbe SM: Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 1990, 63:228–230.

39. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994, 72:561–566.

40. Munger MA, Johnson B, Amber U, Callahan KS, Gilbert EM: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 77:723–727.

41. MacGowen GA, Mann DL, Kormos RL, Feldman AM, Murali S: Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997, 79:128–131.

42. Andreassen AK, Nordøy I, Simonsen S, Ueland T, Müller F, Froland SS, Gullestad L, Aukrust P: Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 1998, 81:604–608.

43. Calder PC: n-3 polysaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006, 83:1505S–1519S.

44. Calder PC: Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol 2011, 668(Suppl 1):S50–S58.

45. Myhrstad MC, Retterstol K, Telle-Hansen VH, Ottestad I, Halvorsen B, Holven KB, Ulven SM: Effect of marine n-3 fatty acids on circulating inflammatory markers in healthy subjects and subjects with cardiovascular risk factors. Inflamm Res 2011, 60:309–319.

46. Zhao Y, Joshi-Barve S, Barve S, Chen LH: Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr 2004, 23:71–78.

47. Duda MK, O'Shea KM, Stanley WC: Omega-3 polysaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res 2009, 84:33–41.

48. Neschen S, Moniro K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, Gillum M, Shulman GL: Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 2006, 55:924–928.

49. Ouchi N, Walsh K: Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007, 380:24–30.

50. Osman R, L’Allier PL, Bgharib N, Tardif JC: Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc Health Risk Manag 2006, 2:221–237.

51. Nakou ES, Liberopoulos EN, Miliou HI, Eifaš MS: The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol 2008, 6:258–270.